Table 1 Current clinical trials on EGFR-TKIs for LM
From: The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancer
Author | Years | N | Study type | Regimen | VP | Histology | Prior EGFR-TKIs | Outcomes | References |
|---|---|---|---|---|---|---|---|---|---|
Yang | 2015 | 6 | Retrospective | Standard-dose erlotinib + PP | No | EGFRMT NSCLC | Gefitinib | Intracranial CR 1/6, PR 3/6; neurological symptoms improved 5/5, PS improved 6/6; median PFS 8.5 months; median OS 9.0 months | Yang et al. (2015) |
Kawamura | 2015 | 12 | Retrospective | High-dose erlotinib ± WBRT/Bevacizumab | No | EGFRMT NSCLC | Gefitinib/erlotinib | Intracranial ORR 3/10; neurological symptoms improved 6/12, PS improved 4/12; median PFS 2.3 months; median OS 6.2 months | Kawamura et al. (2015) |
Jackman | 2015 | 7 | Phase I | High-dose gefitinib | No | EGFRMT NSCLC | Gefitinib/erlotinib/Vandetanib | Intracranial ORR 0/7; neurological symptoms improved 4/7; median PFS 2.3 months; median OS 3.5 months | Jackman et al. (2015) |
Gong | 2015 | 21 | Retrospective | High-dose/Standard-dose Icotinib ± ITC/WBRT/Chemotherapy | No | EGFRMT NSCLC | Icotinib partly | Intracranial ORR 8/21; neurological symptoms improved 18/20, PS improved 17/21; median OS 10.1 months | Gong et al. (2015) |
Lin | 2014 | 1 | Case report | Afatinib + cetuximab | No | EGFRMT ADC | High-dose erlotinib, gefitinib | Intracranial PR; neurological symptoms improved; OS 5 months | Lin et al. (2014) |
Kwon | 2014 | 37 | Retrospective | EGFR-TKIs | No | NSCLC | EGFR-TKIs partly | Median OS 10.5 months versus 3.0 months with or without EGFR-TKIs therapy after LM | Kwon and Chie (2014) |
Lee | 2013 | 25 | Retrospective | Gefitinib/erlotinib ± ITC/WBRT | No | NSCLC | Gefitinib/erlotinib | Intracranial ORR 5/9 versus 3/9, median OS 9.5 months versus 4.4 months with erlotinib or gefitinib therapy after LM | Lee et al. (2013) |
Kuiper | 2013 | 2 | Case reports | High-dose pulsatile erlotinib + Chemotherapy | No | EGFRMT NSCLC | Erlotinib/afatinib | Intracranial PR 2/2; neurological symptoms improved 2/2 | Kuiper and Smit (2013) |
Yuan | 2012 | 1 | Case report | High-dose gefitinib + Pemetrexed | No | EGFRMT ADC | Gefitinib | Intracranial PFS 6.0 months, neurological symptoms improved | Yuan et al. (2012) |
Umemura | 2012 | 91 | Retrospective | Gefitinib/erlotinib ± ITC/WBRT | No | NSCLC | – | Median OS 5.3 months versus 2.3 months with or without EGFR-TKIs therapy after LM | Umemura et al. (2012) |
Togashi | 2012 | 1 | Case report | Erlotinib | No | EGFRMT ADC | Erlotinib/gefitinib | Intracranial PR; neurological symptoms improved; PS improved; PFS 8.0 months | Togashi et al. (2012) |
Park | 2012 | 50 | Retrospective | Erlotinib/gefitinib ± WBRT | No | NSCLC | EGFR-TKIs partly | Median OS 4.3 months for all patients, median OS was longer with patients receiving EGFR-TKIs than not (p = 0.002) | Park et al. (2012) |
Masuda | 2011 | 3 | Case reports | Erlotinib | No | EGFRMT ADC | Gefitinib | Neurological symptoms improved 2/3; PS improved 2/3; median OS 93 days | Masuda et al. (2011) |
Grommes | 2011 | 9 | Retrospective | High-dose pulsatile erlotinib | No | EGFRMT NSCLC | Erlotinib/Afatinib/gefitinib | Intracranial ORR 6/9; neurological symptoms improved 18/20,; median PFS 2.7 months; median OS 12.0 months | Grommes et al. (2011) |
Clarke | 2010 | 1 | Case report | High-dose pulsatile erlotinib | Yes | EGFRMT NSCLC | Erlotinib | Intracranial PR; OS 14 months | Clarke et al. (2010) |
Yi | 2009 | 11 | Retrospective | Erlotinib/gefitinib ± ITC | No | NSCLC | Gefitinib partly | Clinical response 9/11; >6 months OS 8/11 | Yi et al. (2009) |
Katayama | 2009 | 4 | Retrospective | Erlotinib | No | EGFRMT ADC | Gefitinib | Intracranial ORR 2/3; neurological symptoms improved 3/4, PS improved 1/4; median OS 4.0 months | Katayama et al. (2009) |
Dhruva | 2009 | 1 | Case report | High-dose pulsatile erlotinib | No | NSCLC | Erlotinib | Intracranial PR; neurological symptoms improved, PS improved | Dhruva and Socinski (2009) |
Jackman | 2006 | 1 | Case report | High-dose gefitinib | No | EGFRMT ADC | Gefitinib | Intracranial PR; neurological symptoms improved, PS improved | (Jackman et al. 2006) |
Choong | 2006 | 1 | Case report | Gefitinib | No | EGFRMT ADC | Erlotinib | Intracranial PR; neurological symptoms improved, PS improved | (Choong et al. 2006) |